2025 Cell and Gene Therapy Report

The Next Chapter in Cell and Gene Therapy

Cell and gene therapies (CGTs) are rewriting the future of medicine. With more products entering the market and greater investments fueling innovation, the potential to transform patient care has never been greater. But structural barriers around reimbursement, infrastructure, and access still stand in the way of reaching patients at scale.

The 2025 Cell and Gene Therapy Report captures this dynamic moment of growth and change. This year’s report illustrates the barriers facing the industry and progress toward wider CGT adoption through research with physicians and payers, an analysis of pipeline data, and perspectives from leading CGT experts. The report underscores the collective effort needed to ensure CGT innovation translates into impact for patients everywhere.

Inside the 2025 Report

90%

of payers believe CGTs are safe and effective

“The CGT field is reaching an inflection point. Progress is undeniable, but so are the barriers standing in the way of broader access.”

— Joe DePinto, Head of Cell, Gene and Advanced Therapies, McKesson

Physician experience with CGTs is growing, with an average of 25 patients treated annually in 2025 vs 17 in 2024

235+

new therapies in the CGT pipeline

See the Map of QTCs

For many patients, the miles between their home and a Qualified Treatment Center (QTC) are as significant a hurdle as the disease itself.

Our 2025 analysis identified 436 named QTCs across 102 geographic markets in the US. Many of these centers are clustered in large cities, leaving millions of Americans with limited access to cell and gene therapy.

Explore the interactive map to see where CGT care is available today and where gaps persist.

Go to the map